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Introduction
The general practitioner (GP) is in a 
unique position in South Africa and 
elsewhere in the world when it comes to 
female and adolescent health. After es-
tablishing rapport, the GP can provide 
confidential advice, guidance and treat-
ment with regard to a young patient’s 
reproductive health. It is vital that the 
adolescent makes an informed choice 
about her sexual activity and behav-
iour, her method of contraception and 
issues pertaining to her health in gen-
eral. These discussions and counsel-
ling sessions should be informative but 
non-judgmental and non-threatening, as 
the main outcome is to prevent teenage 
pregnancy and its associated devastat-
ing repercussions on the adolescent, 
her family, the child born to such a 
young mother, and the public health 
sector. Contraceptive choices today are 
numerous – especially in the category of 
hormonal contraception. New options 
with regard to delivery systems and 
new progestogens with novel side-ef-
fect profiles have expanded the choices 
for first-time users. It is possible to find a 
contraceptive to suit every patient’s indi-
vidual needs, with added benefits such 
as cycle control, relief of dysmenorrhoea 
and treatment for acne. A thorough un-
derstanding of the patient’s needs and 
circumstances (ta-king into account 
the first and third world setting in South 
Africa) is necessary. A holistic approach 
must be followed, and individualising 
each patient will aid in compliance and 
continuing medical input and care well 
into her reproductive years, until such 
time when she plans her first child and 
thereafter.1
Hormonal contraception
Combined (estrogen and progester-
one) contraceptives
The combined oral contra-ceptive pill 
(COCP)
Product selection
Two synthetic estrogens are available 
in South Africa: mestranol and ethinyl-
estradiol (EE).2 As 50µg of mestranolis 
metabolised to 35µg of EE, in theory-
there is only one active estrogen.3 In
practice today, low-dose EEcontaining 
COCPs (20µg-35µg) have replaced 
COCPs with a content of 50µg EE or 
more.3 The EE is used in combination 
with various progestogens in varying 
dosages. (see Table I)
The COCP is classified into three 
subgroups:2
•  Monophasic pill: constant amounts of 
progesterone and estrogen through-
out the cycle.
•  Biphasic pill: estrogen dosagestable, 
but the last 10 active pills contain a 
higher dosage of progesterone.
•  Triphasic pill: estrogen and proges-
terone levels are changed at two 
stages to imitate the normal men-
strual cycle.
At first glance, it seems a daunting task 
to select a product. But it is possible to 
prescribe and find the exact pill to suit 
each individual patient at the lowest 
dose that will provide contraception, 
with the fewest side effects and added 
secondary benefits (see Table I).
The various progestogens can be 
profiled as follows:3
•  Norethisterone (NET) – This is a low-
potency progestogen, and fairly non-
androgenic. The effect on the en-
dometrium is suppressive and with-
drawal bleeding is very light, some-
times even absent. In some women 
it causes breast tenderness, bloating 
and nausea because of the relative 
oestrogenicity.
•  Levonorgestrel (LNG) – A more po-
tent progestogen and more andro-
genic (can cause acne and weight 
gain) than norethisterone. Cycle con-
trol is usually good.
•  Desogestrel (DSG) – This progesto-
gen is more oestrogenic and there is 
a slightly higher risk of thrombo-em-
bolism in users of pills containing this 
hormone.4 There are however, few-
er androgenic side effects (irritability, 
weight gain and acne).
•  Gestodene (GSD) – The same attri-
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butes as for DSG apply to this pro-
gestogen. It also has excellent cycle 
control.
•  Cyproterone acetate – Anantiandro-
genic progestogen, this is an effec-
tive drug against acne and hirsutism, 
as well as an effective contraceptive.
•  Norgestimate – A prodrug, which is 
rapidly absorbed and metabolised 
and converted to norgesterol.
•  Drospirenone – Antiandrogenic and 
an analogue of spirinolactone, it has 
a mild diuretic effect, which is useful 
in patients who experienced fluid re-
tention on other COCPs.5 It provides 
safe prevention against pregnancy. 
After a thorough history has been ob-
tained from the patient to rule out ab-
solute contra indications to the use of 
COCP (see Table II), a pregnancytest 
(if indicated) and a blood pressure 
measurement are vital before com-
mencing with oral contraception.6 A 
pelvic examination can be deferred to 
another visit.7
Guillebaud advises that, in young 
first users, a low-dose LNG or NET 
product should remain the usual first 
choice, because an unknown subgroup 
that is exposed to venous thrombo-
embolism will be included.4 It is useful 
to prescribe a three to four-month trial 
of a low-dose contraceptive and if side 
effects persist, the combination of the 
COCP can be changed accordingly.3
Cycle control is a huge benefit in 
the adolescent, since an ovulation due 
to immaturity is a common cause of 
irregular cycles. Good cycle control 
also means more predictable periods 
and less iron deficiency anaemia due 
to menorrhagia. 
Causes of cycle abnormalities
It is vital to bear in mind that irregular 
cycles are a symptom and not a diagno-
sis, and other causes such aspolycystic 
ovary syndrome (PCOS), eating disor-
ders, female athlete syndrome, thyroid 
disease and stress must be ruled out.8 
PCOS is better diagnosed in adole-
scence than later in life, since guidance 
can be given at an early stage to weight 
management and other modifiable life-
style issues such as stress and the risks 
of smoking.8
Extended cycling is currently of 
great interest to adolescents and GPs, 
since recent findings suggest that many 
adolescents would prefer to menstruate 
less frequently.9 Extended cycling with 
COCPs (monophasic) decreases the 
frequency of the seven-day hormone-
free interval. This method was histori-
cally used to treat endometriosis, dys-
menorrhoea and menorrhagia, but can 
also be used to treat disorders prevalent 
in the pill-free interval, such as migraine, 
irritable bowel syndrome and epilepsy.9 
It has also been found that shortening 
or eliminating the hormone-free interval 
may increase contraceptive efficacy 
due to greater ovarian suppression.8 
Currently there is no evidence that this 
method of cycle control is associated 
with increased risk due to more hor-
mone exposure than during traditional 
cycling. Breakthrough bleeding in a 
cycle is a common complaint in the GP 
office setting once a patient is on the 
COCP. It is useful to ask in which part 
of the cycle it occurs. If it occurs in the 
early part of the cycle, use a COCP with 
a higher oestrogen content. If break-
through bleeding exists in the mid to late 
part of the cycle, a COCP with greater 
endometrial activity could be used, such 
as a product with a more potent proges-
togen, or a change could be made to a 
product with a lower oestrogen content.2 
A patient can be reassured that if no 
pills were missed or taken late, and no 
vomiting or drug interactions took place, 




This square adhesive patch, measu-
ring 4.5 cm x 4.5 cm, is an exciting 
new delivery system. It is placed on 
the skin once a week for three continu-
ous weeks. A continuous daily serum 
level of 20µg ethinylestradiol and 150µg 
norelgestromin (the primary active me-
tabolite of norgestimate) is delivered. 
This is followed by a week of non-use to 
allow a withdrawal bleed.5 Clinical trials 
show that there is a greater incidence 
of perfect use than observed with oral 
•  Reduction in menstrual disorders such as irregular cycles, menorrhagia 
    (and resultant less occurrence of iron deficiency anaemia), dysmenorrhoea 
     and PMS1,2
•  Reduction of occurrence of functional ovarian cysts and carcinoma2,3
•  Reduction of occurrence of endometrial carcinoma2,4
•  Reduction in occurrence of ectopic pregnancy2,4
•  Some protection against pelvic inflammatory disease3,4
•  Reduction in benign breast disease4
•  Probable reduction in risk of rheumatoid arthritis4
Table I: Non-contraceptive benefits of COCP use
Absolute contraindication to the use of the 
COCP
Pregnancy
Undiagnosed genital tract bleeding
Risk factor for venous 
tromboembolism
Overweight BMI >39
Family history of VTEs
No work-up done of patient
Known congenital or acquired trombophilia
Systemic Lupus Erythematosus
Risk factors for arterial cardiovascu-
lar disease
Cigarette smoking > 40 per day
Migraine Focal aura symptoms, severe or ergotamine treated
Hypertension BP > 160/100 mmHg
Liver disease
Liver adenoma and carcinoma
Cholelithiasis (COCPs can be resumed after 
cholecystectomy)
Acute hepatic porphyrias
Oestrogen-dependent tumour Breast cancer
Table II: Absolute contraindication to the use of the COCP4
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contraceptives in all age groups and 
the efficacy and side effects are com-
parable with COCPs.5 Another benefit 
in users such as adolescents is that the 
contraceptive efficacy is maintained 
even if patch replacement only occurs 
two days after the patch-free week.5 
Side effects specific to the contra-
ceptive patch include:10
1.  Adhesive issues related to the de-
livery system, although detachment 
rates and skin sensitivity is reported 
by < 3% of users.
2.  Increase in mild breast discomfort,but 
after the first two to three cycles, this 
symptom improves.
3.  A potential decrease in efficacy in 
women weighing more than 90 kg. 
Progestogen-only contraception 
Injectable progesterone 
Two types of injectable progesterone 
are available in South Africa:
Depot medroxyprogesteroneacetate 
(DMPA Depo Provera®)
•  A dosage of 150 mg DMPA is inject-
ed deep intra muscularly every 12 
weeks. This method requires minimal 
effort on behalf of the user, and is a 
very effective contraceptive. It has a 
failure rate of 0 - 1 per 100 woman 
years.4 It shares most of the non-
contraceptive benefits of the COCP, 
including protection against pelvic 
infection and treatment of endome-
triosis, and can reduce the frequency 
of seizures in epilepsy.4
•  Unwanted effects are irregular bleed-
ing, amenorrhea (with continued use) 
and a delay of10 months in the return 
of fertility after discontinuation of the 
method.4 There is also a concern 
among young women that they may 
gain weight, but they can be advised 
that it may simply reflect the normal 
increase in weight expected during 
the early reproductive years.10
•  Much attention has been focused on 
the link between prolonged use of 
DMPA, a state of relative hypo-oes-
trogenicity and a resultant adverse 
effect on bone density. Current evi-
dence does indicate a link, as bone 
density decreases with a longer 
duration of DMPA use.4 According 
to the limited data available, there 
is at least partial recovery of bone 
mineral density (BMD) after cessa-
tion of DMPA.4  It is evident that more 
data and studies are needed. Several 
guidelines can be followed, such as 
the statement by the Faculty of Fam-
ily Planning and Reproductive Health 
Care and the key points of the MHRA 
Updated Prescribing Advice:
1.  In adolescents, DMPA may be used 
as first-line contraception, but only 
after other methods have been dis-
cussed with the patient and consi-
dered to be unsuitable and unac-
ceptable.
2.  In woman of all ages, careful evalua-
tion of the risks and benefits of treat-
ment should be carried out in those 
who wish to continue use for more 
than two years.
3.  In woman with significant lifestyle 
and/or medical risk factors for os-
teoporosis, other methods should be 
considered.
Other lifestyle factors that impact on 
achieving optimal bone mass in the 
adolescent include an adequate intake 
of dietary calcium (>1300mg), physical 
activity, and the restriction of tobacco 
use. The clinician could target these 




•  This injectable is given eight weekly 
at a dosage of 200 mg intramuscu-
larly. It is a slightly more androgenic 
compound than the DMPA. When 
the method is discontinued, fertility 
returns within seven months.2 
Progestogen-only pill (POP) 
(mini-pill)
Two types of POPs are available in SA 
(see Table IV). This method of contra-
ception needs a meticulous pilltaker (a 
trait teenagers are notoriously lacking), 
since every dosage must be taken daily 
within a three-hour period. The pill is 
taken continuously. If taking the pill 
is delayed for three hours, additional 
precautions or abstinence is needed 
for seven days.4 The failure rate is 
higher than with the COCP.3 A patient 
may experience irregular bleeding or 
amenorrhea. If the first-time user is post-
partum and exclusively breastfeeding, 
this is an excellent choice for the first six 
months if the patient is amenorrhoeic.4  
It does not influence lactation and is 
safe in the thrombogenic weeks post 








Minesse® EE 15 GSD 60
Mirelle® EE 15 GSD 60
Melodene® EE 20 GSD 75
Mercilon® EE 20 DSG 150
Nordette® EE 30 LNG 150
Femodene® EE 30 GSD 75
Minulette® EE 30 GSD 75
Marvelon® EE 30 DSG 150
Yasmin® EE 30 drospiridone 3.0mg
Triphasil® EE 30/40/30 LNG 50/75/125
Logynon® EE 30/40/30 LNG 50/75/125
Tri-Minulet® EE 30/40/30 GSD 50/70/100
Triodene ED® EE 30/40/30 GSD 50/70/100













Trinovum® EE 35 NET 0.5/0.75/1 mg
Biphasil® EE 50 LNG 50/125
Ovral® EE 50 NGS 500
 Table III: COCPs available in SA 
*Unless otherwise stated
EE – Ethinyl Estradio; LNG – levonorgestrel; DSG – desogestrel; NET – norethisterone; GSD – gestodene
Review
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Post-coital contraception
Post-coital contraception is also called 
emergency contraception. It is used to 
prevent unwanted pregnancy after un-
protected sexual intercourse or failure 
of a barrier method. Three methods are 
available:6
•  Combined oral  emergency 
contracept ive
  Two tablets containing 50µg of EE 
and 0.25 mg of LNG each are taken 
12 hours apart (maximum of two 
doses). Benefit can be obtained up 
to 72 hours after intercourse. The 
large dose of oestrogen can cause 
nausea and vomiting, and it may 
be necessary to prescribe an anti-
emetic such as domperidone 10 
mg with each dose. According to a 
WHO study, overall efficacy is 97%.4
•  Progesterone-only emergency 
 contraceptive 
  A maximum of two doses of one 
tablet of 0.75 mg levonorgestrel is 
taken 12 hours apart. Benefit can 
be obtained up to 72 hours after 
intercourse. The main advantage 
of this method, according to a 
WHO trial, is that it is more effective 
than the COEC (99%), especially 
if treatment begins within 24 hours 
of exposure.3 There are also fewer 
side effects of nausea and vomiting.
• Copper IUD
  This option is not advised for nul-
liparous women, but according to 
a WHO study it has an efficacy of 
99,9%.4 It can be inserted up to five 
days after ovulation. The  contraindi-
cations would be as for any other IUD 
insertion. 
The following are special prescriber’s 
points regarding hormonal emergency 
contraception:4
•  Every delay of 12 hours in treatment 
increases the failure by 50%. The 
patient should be counselled in this 
regard.
•  If the patient is on an enzyme-inducer 
drug, the dose must be increased by 
50%.
•  If the dose is vomited within two 
hours of ingestion, the patient can 
take a further dose.
•  Contraception in the current cycle
 and long term should be discussed.
Intrauterine Contraceptive Devices 
(IUCDs)
This method of contraception will be 
discussed briefly, as it is of benefit to a 
select group of the patient population. 
The two most widely used IUCDs are the 
copper-containing devices (i.e. Copper-
T®) and the levonorgestrel intrauterine 
system (Mirena®). Nulliparity/young age 
and a lifestyle conducive to STD risk are 
relative contraindications to the use of 
IUCDs.4 However, this is a very safe 
method of contraception with a failure 
rate of 0.6 - 0.8 pregnancies per 100 
women in the first year of use of the cop-
per-containing device and 0.1 for the le-
vonorgestrel (LNG) intrauterine system.6 
For many teenagers, the initial pelvic 
examination and insertion are traumatic, 
but once in place, it is an effective long-
term method. Should side effects occur, 
the process is immediately reversible.10 
Before insertion, the patient must be 
carefully screened for STDs, since in-
sertion in the presence of an STD poses 
an unacceptable health risk.10 Ongoing 
advice and counselling regarding STDs 
should be given, and teenagers with 
IUCDs should be urged to use condoms 
and abstain from high-risk sexual be-
haviour.10 The side effects and benefits 
of IUCDs are listed inTable V. 
Barrier methods 
Male condom
The male condom remains the most-
widely used contraceptive method 
among teenagers and the most widely 
used mechanical contraceptive in the 
world today.4  The condom has a failure 
rate of 2-15 per 100 woman years and 
it should be recommended that it be 
used in addition to another contracep-
tive.4,6 Most condoms are made of latex. 
Imperfections of manufacture occur in 
about three out of every 1 000 condoms 
and failure of a condom can be attri-
buted to this fact and primarily to er-
rors of technique. Correct condom use 
should be promoted in adolescents to 
additionally reduce the risk of trans-
mission of HIV and other STDs.10 A 
huge benefit is that it is an inexpensive 
method and widely available. 
Future options in contraceptives 
Combination injectable (Lunelle®/
Lunella®) 
This product is being reviewed by the 
US Food and Drug Administration. It 
is a popular form of contraceptive in 
Central and South America.5 The injec-
tion contains 5 mg of estradiol cypionate 
and 25 mg of medroxyprogesterone 
acetate, and is given intramuscularly 
every 28 days.5 The efficacy for preg-
nancyprevention and the side effect 
profile is comparable to the triphasic 
COCP.5  The non-daily method of use 
improves compliance in the adoles-
cent patient. There is also good cycle 
control. A predictable bleed occurs 
two to three weeks after the first injec-
tion. Return to fertility is quicker than 
with the progestogen-only injection.7
Vaginal ring (NuvaRing®)
This product may provide a suitable 
choice of contraception for adolescents 
in the future. The device is a flexible 
polymer ring placed into the vagina by 
the patient herself. It is kept in place 
for three weeks and removed for one 
week each month to allow a withdrawal 
bleed. The ring releases 15µg of ethinyl 
estradiol and 120µg of etonorgestrel 
(the active metabolite of desogestrel) 
daily.5 The ring has a Pearl index of 0.65 
per 100 woman years with perfect use.6 
It can be left in situ during intercourse 
and usually does not cause discomfort 
to either partner. It can be removed for 
brief intervals (< 3 h). Cycle control is 
excellent in ring users.5 
Contraceptive implant: single rod 
implant (Implanon®)
The implant provides three years of 
continuous contraception by releasing 
Table IV:  Progestogen-only pills available in 
South Africa
Micro-Novum® Norethisterone 35 µg
Microval® Levonorgestrel 30 µg
Table V: Side effects and benefits of IUCDs
Side effects Benefits
LNG intra-uterine system Breakthrough bleeding 1st 
3-6 months, then 
amenorrhea
Dosing every 5 years, less 
menstrual blood loss, less 
dysmenorrhoea
Copper-containing device Menorrhagia, 
dysmenorrhoea
Dosing every 10 years, 
non-hormonal form of 
contraception
Adapted from As-Sanie et al., Pregnancy prevention in adolescents.6
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steady hormone levels of etonorgestrel 
(the active metabolite of desogestrel) 
into the body.5  The failure rate is 0-0.2% 
and it is thus an excellent contracep-
tive.6 Follicular activity is not suppressed 
and oestrogen levels remain adequate 
for the maintenance of bone density.3 
The implant requires surgical insertion 
and removal. An unfortunate side effect 
is an increase in weight (up to 3.5% in 
BMI7) and irregular bleeding patterns.5
In conclusion
The contraceptive choices in this mo-
dern day are numerous. A teenager who 
has been well informed of all the con-
traceptive options available to her can 
be guided to choose the best method to 
suit her needs. Often one appointment is 
too short for all of the above to happen. 
An informative leaflet on contraceptive 
choices can be given to the patient to 
take home: thus two or more appoint-
ments may be needed for adequate 
counseling and the initiation of contra-
ception. Long-term follow up of the pa-
tient is vital: each visit is an opportunity 
to promote woman wellness and health 
for years to come.  
See CPD Questionnaire, page 42
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